Acelyrin (NASDAQ:SLRN - Get Free Report) is expected to be issuing its Q1 2025 quarterly earnings data before the market opens on Tuesday, May 13th. Analysts expect the company to announce earnings of ($0.95) per share for the quarter.
Acelyrin (NASDAQ:SLRN - Get Free Report) last announced its quarterly earnings data on Wednesday, March 19th. The company reported ($0.79) earnings per share for the quarter, beating analysts' consensus estimates of ($0.86) by $0.07. On average, analysts expect Acelyrin to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Acelyrin Price Performance
SLRN stock traded down $0.10 during midday trading on Friday, hitting $2.36. 395,887 shares of the stock traded hands, compared to its average volume of 1,202,568. Acelyrin has a 1-year low of $1.85 and a 1-year high of $7.25. The stock's fifty day simple moving average is $2.46 and its 200-day simple moving average is $3.11. The firm has a market cap of $238.14 million, a P/E ratio of -0.96 and a beta of 1.07.
Insider Buying and Selling
In other Acelyrin news, CEO Mina Kim sold 17,986 shares of the company's stock in a transaction on Monday, March 17th. The stock was sold at an average price of $2.74, for a total value of $49,281.64. Following the sale, the chief executive officer now owns 671,753 shares of the company's stock, valued at approximately $1,840,603.22. This represents a 2.61 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 13.60% of the company's stock.
About Acelyrin
(
Get Free Report)
Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.
Featured Stories
Before you consider Acelyrin, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Acelyrin wasn't on the list.
While Acelyrin currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
